Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology

Yıl: 2020 Cilt: 54 Sayı: 2 Sayfa Aralığı: 71 - 75 Metin Dili: İngilizce DOI: 10.4274/turkderm.galenos.2020.80000

Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology

Öz:
Anahtar Kelime:

Konular:
Fen > Tıp > Dermatoloji

COVID-19 pandemisi süresince ürtiker ve atopik dermatitte sistemik tedavilerin kullanımına ilişkin öneriler: Türk Dermatoloji Derneği Dermatoallerji Çalışma Grubu Bildirisi

Öz:
Anahtar Kelime:

Konular:
Fen > Tıp > Dermatoloji
Belge Türü: Makale Makale Türü: Editöre Mektup Erişim Türü: Erişime Açık
  • 1. T.C Sağlık Bakanlığı Korona Tablosu [Web Document]. URL https://covid19. saglik.gov.tr/ [accessed on 22 April 2020].
  • 2. Villani A, Scalvenzi M, Fabbrocini G: Teledermatology: a useful tool to fight COVID-19. J Dermatolog Treat 2020;13:1.
  • 3. Lebwohl M, Rivera-Oyola R, Murrell DF: Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol 2020;82:1217-8.
  • 4. Wollenberg A, Flohr C, Simon D, et al: European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis. J Eur Acad Dermatol Venereol 2020.
  • 5. Shakshouk H, Daneshpazhooh M, Murrell DF, Lehman JS: Treatment considerations for patients with pemphigus during the COVID-19 pandemic. J Am Acad Dermatol 2020.
  • 6. Li X, Geng M, Peng Y, Meng L, Lu S: Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020;10:102-8.
  • 7. Shi Y, Wang Y, Shao C, et al: COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020;27:1451-4.
  • 8. Bikdeli B, Madhavan MV, Jimenez D, et al: COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol 2020.
  • 9. Zhang J, Dong X, Cao Y, et al: Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020.
  • 10. Jordan RE, Adab P, Cheng KK: Covid-19: risk factors for severe disease and death. BMJ 2020;368:m1198.
  • 11. Price KN, Frew JW, Hsiao JL, Shi VY: COVID-19 and Immunomodulator/ Immunosuppressant Use in Dermatology. J Am Acad Dermatol 2020;82:e173-e5.
  • 12. Zhao ZT, Ji CM, Yu WJ, et al: Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2016;137:1742-50.e4.
  • 13. Eichenfield LF, Bieber T, Beck LA, et al: Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. Am J Clin Dermatol 2019;20:443-56.
  • 14. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C: Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020;79:667-8.
  • 15. D’Antiga L: Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transplant 2020.
  • 16. de Lang A, Osterhaus ADM, Haagmans BL: Interferon-γ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology 2006;353:474-81.
  • 17. Storm C, Hawill B, Geraci J: Repurposing Dupilumab May Treat Advanced COVID-19 Patients With Severe Acute Respiratory Syndrome By Mitigating. (Preprint) (https://www.researchgate.net/publication/340084903_ Repurposing_Dupilumab_May_Treat_Advanced_COVID-19_Pa-_tients_ With_Severe_Acute_Respi-_ratory_Syndrome_By_Mitigating_Cytokine_ Storm.) [accessed on 23 April 2020].
  • 18. Ferrucci S, Romagnuolo M, Angileri L, Berti E, Tavecchio S: Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports. J Eur Acad Dermatol Venereol 2020.
  • 19. Patruno C, Stingeni L, Fabbrocini G, Hansel K, Napolitano M: Dupilumab and COVID-19: what should we expect? Dermatol Ther 2020.
  • 20. Pathoulas JT, Stoff BK, Lee KC, Farah R: Ethical outpatient dermatology care during the coronavirus (COVID-19) pandemic. J Am Acad Dermatol 2020;82:1272-3.
  • 21. Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG: Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Infectious complications and vaccination recommendations. J Am Acad Dermatol 2017;76:191-8.
  • 22. Russell CD, Millar JE, Baillie JK: Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473-5.
  • 23. Management of Patients with Confirmed 2019-nCoV | CDC [Web Document]. URL https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinicalguidance- management-patients.html [accessed on 19 April 2020].
  • 24. Savic S, Marsland A, McKay D, et al: Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care. Allergy, Asthma Clin Immunol 2015;11:21.
  • 25. Kulthanan K, Chaweekulrat P, Komoltri C, et al: Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review. J Allergy Clin Immunol Pract 2018;6:586-99.
  • 26. Schneeweiss MC, Perez-Chada L, Merola JF: Comparative Safety of Systemic Immuno-modulatory Medications in Adults with Atopic Dermatitis. J Am Acad Dermatol 2019;31:S0190-9622.
  • 27. Ou Z, Chen C, Chen A, Yang Y, Zhou W: Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis. Int Immunopharmacol 2018;54:303-10.
  • 28. Zhao ZT, Ji CM, Yu WJ, et al: Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2016;137:1742-50e4.
  • 29. Esquivel A, Busse WW, Calatroni A, et al: Effects of Omalizumab on Rhinovirus Infections, Illnesses, and exacerbations of asthma. Am J Respir Crit Care Med 2017;196:985-92.
  • 30. Bressan AL, Silva RS da, Fontenelle E, Gripp AC: Immunosuppressive agents in Dermatology. An Bras Dermatol 2010;85:9-22.
  • 31. XOLAIR® Omalizumab For Subcutaneous Use [Web Document]. URL https:// www.accessdata.fda.gov/drugsatfda_docs/label/2003/omalgen062003LB. pdf [accessed on 23 April 2020].
  • 32. EMA Dupixent Assessment report [Web Document] URL https://www. ema.europa.eu/en/documents/assessment-report/dupixent-epar-publicassessment- report_en.pdf [accessed on 23 April 2020].
  • 33. Zuberbier T, Aberer W, Asero R, et al: The EAACI/GA2LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. Allergy 2018;73:1393-1414.
  • 34. Liu H, Farley JM: Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport. BMC Pharmacol 2005;5:8.
  • 35. Niemeyer-van der Kolk T, van Maaren MS, van Doorn MBA: Personalized omalizumab treatment improves clinical benefit in patients with chronic spontaneous urticaria. J Allergy Clin Immunol 2018;142:1992-4.
  • 36. Denman S, Ford K, Toolan J, et al: Home self-administration of omalizumab for chronic spontaneous urticaria. Br J Dermatol 2016;175:1405-7.
APA SALMAN A, ALPER S, ATAKAN N, BAŞKAN E, BORLU M, CANBOLAT F, ERDEM T, ERDEM Y, GÜL Ü, KARTAL S, KOCA R, KÜÇÜK Ö, ÖĞRETMEN Z, ÖZKAYA E, SARICAOĞLU H, ŞAVK E, TAŞKAPAN O, UTAŞ S, GÖNCÜ E (2020). Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology. Türkderm Türk deri hastalıkları ve frengi arşivi, 54(2), 71 - 75. 10.4274/turkderm.galenos.2020.80000
Chicago SALMAN Andaç,ALPER Sibel,ATAKAN Nilgün,BAŞKAN Emel BÜLBÜL,BORLU Murat,CANBOLAT Filiz,ERDEM Teoman,ERDEM Yasemin,GÜL Ülker,KARTAL Selda Pelin,KOCA Rafet,KÜÇÜK Özlem SU,ÖĞRETMEN Zerrin,ÖZKAYA Esen,SARICAOĞLU Hayriye,ŞAVK Ekin,TAŞKAPAN Oktay,UTAŞ Serap,GÖNCÜ Emek Kocatürk Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology. Türkderm Türk deri hastalıkları ve frengi arşivi 54, no.2 (2020): 71 - 75. 10.4274/turkderm.galenos.2020.80000
MLA SALMAN Andaç,ALPER Sibel,ATAKAN Nilgün,BAŞKAN Emel BÜLBÜL,BORLU Murat,CANBOLAT Filiz,ERDEM Teoman,ERDEM Yasemin,GÜL Ülker,KARTAL Selda Pelin,KOCA Rafet,KÜÇÜK Özlem SU,ÖĞRETMEN Zerrin,ÖZKAYA Esen,SARICAOĞLU Hayriye,ŞAVK Ekin,TAŞKAPAN Oktay,UTAŞ Serap,GÖNCÜ Emek Kocatürk Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology. Türkderm Türk deri hastalıkları ve frengi arşivi, vol.54, no.2, 2020, ss.71 - 75. 10.4274/turkderm.galenos.2020.80000
AMA SALMAN A,ALPER S,ATAKAN N,BAŞKAN E,BORLU M,CANBOLAT F,ERDEM T,ERDEM Y,GÜL Ü,KARTAL S,KOCA R,KÜÇÜK Ö,ÖĞRETMEN Z,ÖZKAYA E,SARICAOĞLU H,ŞAVK E,TAŞKAPAN O,UTAŞ S,GÖNCÜ E Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology. Türkderm Türk deri hastalıkları ve frengi arşivi. 2020; 54(2): 71 - 75. 10.4274/turkderm.galenos.2020.80000
Vancouver SALMAN A,ALPER S,ATAKAN N,BAŞKAN E,BORLU M,CANBOLAT F,ERDEM T,ERDEM Y,GÜL Ü,KARTAL S,KOCA R,KÜÇÜK Ö,ÖĞRETMEN Z,ÖZKAYA E,SARICAOĞLU H,ŞAVK E,TAŞKAPAN O,UTAŞ S,GÖNCÜ E Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology. Türkderm Türk deri hastalıkları ve frengi arşivi. 2020; 54(2): 71 - 75. 10.4274/turkderm.galenos.2020.80000
IEEE SALMAN A,ALPER S,ATAKAN N,BAŞKAN E,BORLU M,CANBOLAT F,ERDEM T,ERDEM Y,GÜL Ü,KARTAL S,KOCA R,KÜÇÜK Ö,ÖĞRETMEN Z,ÖZKAYA E,SARICAOĞLU H,ŞAVK E,TAŞKAPAN O,UTAŞ S,GÖNCÜ E "Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology." Türkderm Türk deri hastalıkları ve frengi arşivi, 54, ss.71 - 75, 2020. 10.4274/turkderm.galenos.2020.80000